Intellectual Property Navigator

NSAID-Derived Selenazoles/Thiazoles as Potential Cancer Therapeutics

ID# 2014-4259
Diagram of Pancreatic Cancer

Technology Summary

Pancreatic cancer (PC) is one of the deadliest cancers, with a median survival of six months and a five year survival rate of only 3-5%, since current chemotherapy is not satisfactory. Through extensive SAR studies on NSAID compounds, we have recently identified a cyclic Se-Aspirin compound, AS-10, designed by incorporating selenazole into acetylsalicylic acid structure, rendering it lethal to cancer cells.

Application & Market Utility

AS-10 is 100 times more potent than gemcitabine, the first-line drug for PC, in killing PC cells. AS-10 was selectively toxic to cancer cells, induced apoptosis, and inhibited tumor growth in a colon cancer xenograft mouse model without any apparent systemic toxicity. In addition to cancer treatment, the AS-10 is useful for patients taking aspirin daily for heart disease and likely useful as an NSAID for pain, fever, and inflammation, while eliminating aspirin related gastrointestinal bleeding issues due to a ~100 times lower dose requirement.

Generate PDF

Have more questions?

Please contact the Penn State Office of Technology Management.


814-865-6277
otminfo@psu.edu